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Abstract
Background: Antidepressant (AD) use has been purported to increase the risk of breast and ovarian cancer, although both
epidemiological and pre-clinical studies have reported mixed results [1–6]. Previous studies in a variety of biomedical fields
have found that financial ties to drug companies are associated with favorable study conclusions [7].
Methods and Findings: We searched English-language articles in MEDLINE, PsychINFO, the Science Citations Index and the
Cochrane Central Register of Controlled Clinical Trials (through November 2010). A total of 61 articles that assessed the
relationship between breast and ovarian cancer and AD use and articles that examined the effect of ADs on cell growth
were included. Multi-modal screening techniques were used to investigate researchers’ financial ties with industry. A
random effects meta-analysis was used to pool the findings from the epidemiological literature. Thirty-three percent (20/61)
of the studies reported a positive association between ADs and cancer. Sixty-seven percent (41/61) of the studies reported
no association or antiproliferative effect. The pooled odds ratio for the association between AD use and breast/ovarian
cancer in the epidemiologic studies was 1.11 (95% CI, 1.03–1.20). Researchers with industry affiliations were significantly less
likely than researchers without those ties to conclude that ADs increase the risk of breast or ovarian cancer. (0/15 [0%] vs 20/
46 [43.5%] (Fisher’s Exact test P = 0.0012).
Conclusions: Both the pre-clinical and clinical data are mixed in terms of showing an association between AD use and
breast and ovarian cancer. The possibility that ADs may exhibit a bi-phasic effect, whereby short-term use and/or low dose
antidepressants may increase the risk of breast and ovarian cancer, warrants further investigation. Industry affiliations were
significantly associated with negative conclusions regarding cancer risk. The findings have implications in light of the 2009
USPSTF guidelines for breast cancer screening and for the informed consent process.
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Introduction
There is some evidence that antidepressant (AD) use is
associated with increased cancer risk [1–6], although the results
from both epidemiological and pre-clinical studies have been
mixed. Reviewing the evidence is a critical public health issue in
light of the increasing prevalence of AD use, especially among
women, and in light of the fact that 1 in 8 women will be
diagnosed with cancer of the breast during their lifetime [8].
Ovarian cancer is the second most frequently occurring female
reproductive cancer and causes more deaths than any other
gynecological cancer [9]. In the US alone, over 27 million people
are taking an AD [10], most of whom are women, for they are
twice as likely as men to be diagnosed with Major Depressive
Disorder and up to three times more likely to be diagnosed with
Dysthymic Disorder [11]. ADs are increasingly being prescribed
for other conditions such as hot flashes, headache, back pain,
neuropathy, sleep-related conditions, anxiety spectrum disorders,
eating disorders, and fibromyalgia [12].
Experimental studies have demonstrated that some ADs
promote tumor growth in animals [5,6,13] although the exact
mechanism by which antidepressants may increase the risk of
tumors is currently unknown. Some ADs, especially SSRIs, are
potent inhibitors of the cytochrome P450 monooxygenase
enzymatic system (a system that metabolizes antineoplastic as well
as other agents) [14]. The expanding pre-clinical and clinical
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research on CYP450 enzymes and the deleterious effects of these
enzymes on the metabolism and therapeutic efficacy of tamoxifen
and other antineoplastic agents [15] has led to concerns that ADs
may directly enhance tumor cell proliferation.
The results of epidemiological studies examining an association
between AD use and breast cancer [1–4] have been inconsistent.
Several of these studies relied on older datasets from before the
widespread use of SSRIs [16–18]. Given the number of women who
are currently taking SSRIs, it is important to systematically review
the most recent pre-clinical and epidemiological studies that have
included this class of antidepressants. Including both epidemiolog-
ical and pre-clinical studies allows for a more thorough assessment
of the literature regarding breast and ovarian cancer risk and AD
use by addressing the issue of biological plausibility.
A growing area of concern in the biomedical sciences, including
oncology, is the potential for financial conflict of interest to
influence the outcome of a study [19,20]. The specific mechanisms
by which industry influence may operate remain unclear and are
most likely varied. For example, researchers who had financial
associations with manufacturers of drugs have been found to be
less likely to criticize the safety of the drug than researchers
without those ties [21]. Other studies have shown an association
between company sponsorship and favorable study outcome [22].
To our knowledge, our study is the first one to examine
researchers’ industry ties and their conclusions on the relationship
between breast and ovarian cancer risk and AD use.
Methods
Data Sources
A list of FDA approved antidepressants was generated and a
search was conducted for English language articles in MEDLINE
(via ISI Web of Knowledge), PSYCINFO, Science Citations
Index, and the Cochrane Database of Controlled Trials Register
(no year limits through November 2010). Following Lawlor et al.
[23], various Medical Subject Headings (MeSH) and free text
terms were combined (e.g., ovarian cancer and antidepressants;
breast carcinoma SSRIs, Tricyclics, MAO inhibitors’’) in order to
generate a list of published human and animal studies that
examined the relationship between ADs and breast and ovarian
cancer. (See Text S1 for a detailed description of the search
strategy.) We identified additional studies by searching the
reference section of selected articles. One of the authors (DC)
has expertise in psychopharmacology and psychogenomics and
provided titles and abstracts of additional studies.
Study Selection
The main criteria for study selection were 1) clinical studies
(including randomized controlled trials, case-control, prospective
and retrospective cohort studies) that assessed the relationship
between AD use and breast and ovarian cancer and 2) preclinical
studies that that assessed the carcinogenic properties of ADs on
tumor lines or in animals. Carcinogenic was defined as
‘‘mutagenetic,’’ ‘‘clastogenetic,’’ ‘‘epigenetic,’’ ‘‘mitogenetic,’’ ‘‘cy-
togenetic,’’ ‘‘genotoxic,’’ ‘‘tumorigenic,’’ neoplastic, ‘‘anti-apoptot-
ic,’’ ‘‘teratogenetic,’’ ‘‘associated with sister chromatid exchanges,’’
and ‘‘induction of genomic instability.’’ We excluded studies that
examined medications other than ADs (e.g., antihistamines which
have a similar molecular structure to ADs), and human studies that
did not empirically assess the relationship between ADs and breast
and ovarian cancer (e.g., anecdotal case reports). We also excluded
epidemiological studies that assessed the relationship between AD
use and other cancer types (e.g. lung) as they were beyond the
scope of this review.
Electronic database searches, reference mining and consultation
with an expert in the field yielded 4,343 citations. Although our
search identified 2,106 clinical trials in the Cochrane Central
Register of Controlled Trials, no randomized or quasi randomized
controlled trials were found to have breast or ovarian cancer as
any outcome measure. After removing duplicates, 4,120 were
excluded based on the title or abstract review (using the study
selection criteria described above), 184 records were requested and
183 (99.5%) were retrieved and reviewed. Of the retrieved records,
122 were rejected because they did not meet study inclusion
criteria (e.g., case reports, editorials, commentaries, assessed
medications other than ADs). Studies that assessed the inter-
relationship among serotonin, SSRIs, certain TCAs, prolactin,
and tamoxifen, and how these inter-relationships affect pharma-
codynamics and cancer risk, were retrieved and underwent a
preliminary review. The remaining articles (N = 61) underwent full
review (Figure 1).
Data Extraction
Any concerns regarding eligibility were discussed and agreed
upon by the investigators. For the 61 articles that met our study
criteria, one investigator (LC) originally abstracted data about the
relationship between ADs and cancer and another (LS for the
epidemiological studies, DC for the pre-clinical ones) indepen-
dently reviewed the data. Abstraction of the data took place prior
to screening for industry associations and reviewers were blinded
with regard to knowledge about the researchers’ industry
associations. Because a main objective of the present study was
to identify the original researchers’ stated conclusions regarding
breast and ovarian cancer risk and ADs, (i.e., No Association vs.
Yes Association) there was little ambiguity in terms of how to
abstract the data. There was one discrepancy which was resolved
by consultation with an outside expert who was blinded to
knowledge about industry associations.
Data Synthesis
Twenty–six epidemiological studies were reviewed [1,2,4,16–
18,24–43] and designated according to authors’ findings as A) No
association B) Yes Association. The latter category included those
studies that found subsamples of women with elevated risks (e.g.,
women over 50) or researchers who reported one or more
statistically significant associations between AD use and cancer
(e.g., significant findings for SSRIs on ER2PR2, ER+/PR2
tumors). In addition, we performed a meta-analysis using the main
effect estimate from each of the 26 epidemiological studies. Most
studies reported effect estimates as odds ratios. In all cases where a
relative risk or hazard ratio was reported, outcome was rare, and
we assumed that these measures approximate the odds ratio. In
studies with two main effects (one for SSRI exposure and one for
TCA exposure or one for risk of breast cancer and one for risk of
ovarian cancer), we used the estimate for the SSRI exposure or for
risk of breast cancer, since the effect of SSRI exposure on the risk
of breast cancer was the most commonly investigated causal effect.
As a sensitivity analysis, we calculated pooled estimates with the
opposite set of estimates included (including the estimate for TCA
exposure from studies that reported separate estimates for SSRI
and TCA use and including the estimate for ovarian cancer from
studies that reported separate estimates for breast and ovarian
cancer). Analysis was also performed separately in the subset of
studies that reported investigating SSRI exposure and the subset of
studies that reported investigating TCA exposure. A random-
effects meta-analysis model was used to account for the
heterogeneity across studies [44] and a funnel plot was examined
for evidence of publication bias. Table S1 provides a detailed
Antidepressants and Breast and Ovarian Cancer
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review and summarizes the study design, participants, exposure
definitions, outcomes and conclusions of these 26 epidemiological
studies (see also Table S2).
Thirty-five pre-clinical (i.e., animal and laboratory) studies were
reviewed [5,6,13,45–76] and designated according to researchers’
findings regarding ADs as being carcinogenic. Following this
review the articles were then designated as A) Positive for
carcinogenesis or B) Negative for carcinogenesis. The ‘‘Negative’’
designation also included studies that found ADs to have an
antineoplastic/antiproliferative effect on cells or tumors. A
detailed review of the pre-clinical studies is provided (see Table
S3; see also Table S4).
We were also interested in discerning whether there was a
connection between industry ties and qualitative conclusions about
cancer risk and AD use. Using multimodal screening techniques,
we examined the relationship between principal investigators’
conclusions and their financial ties to the pharmaceutical industry.
The multi-modal screening methods applied included: MED-
LINE, (used to identify published papers that disclose author
financial interests), and the following internet search engines:
Lexis-Nexis, the U.S. Patent and Trademark Office internet site
on patents awarded, and the internet site for SEC filings. The
development of both criteria for ‘‘holding a financial interest’’ and
for parameters regarding the timing of financial associations (5
years before and five years after a study was published) were based
on standards set by government bodies, journals, and professional
societies as well as based on prior publications [77,78]. Financial
associations for this study included: being an employee of a
pharmaceutical company; receiving honorarium; receiving re-
search funding or research materials (equipment, drugs, cell
cultures, etc); holding equity in a company; being a member or
serving as a consultant to a pharmaceutical corporate board;
providing expert testimony on behalf of the pharmaceutical
company; and holding a patent, patent application or royalties on
AD medication. Two investigators (LC and MM) screened for
financial associations and two (DC and LS) reviewed the
disclosures. No author was coded as having a financial connection
unless there was unambiguous information confirming the
relationship. Only affiliations with manufacturers of ADs were
included in our analysis. Only PIs were screened for industry
associations, thereby minimizing the possibility that studies with
multiple authors would be more likely to have an author with an
industry association (vs. single authored studies). The statistical
relationship between qualitative conclusions and funding source
was analyzed using Fisher’s Exact test. Statistical analysis was
performed with Stata version 8.0 (Stata Corp, College Station,
TX, USA).
Results
Over one-third (38.4% or 10/26) of the epidemiological studies
reported statistically significant findings, of which 8 were case-
control studies and 2 cohort studies. Almost one-third (28.6% or
10/35) of the pre-clinical studies reported a positive finding with
regard to the AD agent being carcinogenic, a tumor promoter, or
genotoxic. Thus, 32.8% (20/61) of the epidemiological and pre-
clinical studies reported an association between ADs and cancer
(Figure 2). There was no strong evidence of publication bias for the
epidemiological studies based on a visual inspection of the funnel
plot, although there is some asymmetry suggesting smaller studies
with negative associations might be under-represented in the
literature (Figure 3).
The pooled odds ratio of 1.11 (95% CI, 1.03–1.20), suggests
that ADs may be associated with a small increase in breast and
ovarian cancer risk (see Table 1). When we instead included the
estimates for TCA and ovarian cancer, the effect was attenuated
(1.05, 95% CI, 0.98–1.14). When we estimated the pooled effect
separately by AD class, we found a slightly stronger effect for
SSRIs (1.07, 95% CI, 0.99–1.51) than for TCAs (1.04, 95% CI
0.95–1.13). Moreover, all studies except one included in the SSRI
Figure 1. Literature search and study selection.
doi:10.1371/journal.pone.0018210.g001
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analysis reported a positive association (Figure 4), whereas the
evidence for TCAs was more mixed, with 9 studies reporting a
positive association, 6 studies a negative association, and one study
a null association (Figure 5).
None of the 4 epidemiological studies for which the principal
investigator (PI) had industry ties reported a positive association
between AD use and cancer risk. Of the 22 studies for which the PI
had no industry ties, 45% (10/22) reported positive findings.
Likewise, none of the 11 pre-clinical studies for which the PI had
industry ties reported positive cancer findings. Of the 24 studies for
which the PI had no industry ties, 42% (10/24) reported that ADs
were carcinogenic, tumor promoters, genotoxic, or neoplastic.
Thus, in total, none of the 15 researchers who had industry ties
reported positive cancer findings, compared with 43% of the
researchers without industry ties. There was a statistically significant
relationship between researchers’ industry ties and conclusions
regarding ADs and cancer (2-sided Fisher’s Exact test P = 0.0012).
Discussion
The meta-analysis of epidemiological studies suggests there may
be a modest increase in the risk of breast/ovarian cancer with the
use of ADs, especially SSRIs. Other potential explanatory factors
for this finding include the role of depression itself rather than
treatment with AD [79], failure to distinguish between short- and
long-term exposure, and a failure to examine a possible non-linear
dose related response as the mechanism for malignant cell
proliferation [5,76,80,81]. This bi-phasic phenomenon is charac-
terized by ‘‘low-dose stimulation and high-dose inhibition’’ [76] of
malignant cell proliferation. Thus, rather than having fewer and
less severe side effects, short-term use and/or low dose
antidepressants could increase the risk of breast and ovarian
cancer in women or exacerbate cancer cell growth in women in
the early stages of breast and ovarian cancer. Large scale
prospective cohort studies of women using SSRIs are needed in
order to determine if ADs cause and/or enhance breast and
ovarian tumor growth. Specifying induction time and exposure
Figure 2. Summary of results.
doi:10.1371/journal.pone.0018210.g002
Figure 3. Funnel plot evaluating the presence of publication
bias.
doi:10.1371/journal.pone.0018210.g003
Table 1. Empirical Bayes effect estimates and weights for the
26 epidemiological studies included in meta-analysis.
Study Weight Effect Estimate 95% CI
Chien 26.08 1.15 0.94 1.40
Coogan 2.23 1.15 0.89 1.49
Coogan 18.60 1.11 0.89 1.38
Coogan 19.33 1.03 0.83 1.28
Cotterchio 18.60 1.14 0.91 1.41
Dalton 57.52 1.00 0.96 1.05
Danielson 9.10 0.98 0.77 1.25
Davis 15.27 1.16 0.92 1.45
Dublin 15.66 0.99 0.79 1.24
Fulton Kehoe 50.83 1.05 0.95 1.16
Gonzalez Perez 37.84 1.03 0.88 1.20
Haque 43.40 1.12 0.98 1.28
Harlow & Cramer 5.02 1.17 0.91 1.51
Harlow 19.16 1.25 1.01 1.55
Haukka 25.51 1.27 1.05 1.55
Kato 12.22 1.22 0.96 1.54
Kelly 8.41 1.16 0.91 1.48
Moorman 28.01 1.01 0.83 1.22
Moorman 18.32 1.07 0.86 1.34
Sharpe 16.54 1.31 1.05 1.64
Steingart 33.17 1.16 0.98 1.38
Tamim 33.29 1.23 1.04 1.46
Wallace 2.81 1.13 0.87 1.46
Wang 39.46 1.06 0.92 1.23
Weiss 8.51 1.08 0.85 1.38
Wernli 47.30 0.93 0.83 1.05
doi:10.1371/journal.pone.0018210.t001
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Figure 4. Empirical Bayes estimates of the study specific and the pooled estimate for SSRIs.
doi:10.1371/journal.pone.0018210.g004
Figure 5. Empirical Bayes estimates of the study specific and the pooled estimate for TCAs.
doi:10.1371/journal.pone.0018210.g005
Antidepressants and Breast and Ovarian Cancer
PLoS ONE | www.plosone.org 5 April 2011 | Volume 4 | Issue 6 | e18210
also will allow future researchers to more accurately assess for dose
and duration effects.
The fact that industry affiliations were significantly associated
with negative findings regarding cancer risk raises public health
and policy issues because there is increasing evidence that financial
ties among industry, investigators, and academic institutions can
affect the research process [82–84]. For example, re-evaluations of
liver tissue of rats exposed to dioxin resulted in different
conclusions about the liver cancer rates in those rats; industry
sponsored reevaluations were associated with fewer cancer
characterizations [85–87], which had an effect on the policy
recommendations. Thus, financial associations between biomed-
ical researchers and the pharmaceutical industry may result in the
publication of incomplete or inaccurate results and imbalanced
recommendations [20,88,90]. This is not to suggest that
researchers with financial associations to industry intentionally
designed studies to produce results favorable to manufacturers of
ADs or that they misrepresented their results. The existence of
researchers’ industry associations points to a generic risk [91] that a
financial conflict of interest may compromise the research process
or undermine public trust; ‘‘conflict[s] of interest do not imply that
any [specific researcher] is improperly motivated.’’ As Thompson,
2009, astutely notes, it is virtually impossible to determine that a
particular decision during the research process was motivated by
secondary interests (e.g., financial gain). Although space precludes
a more extensive discussion, we agree with Thompson [91] that
the generic risk incurred by financial conflicts of interest
undermines public trust. ‘‘[T]he point is to minimize or eliminate
circumstances that would cause reasonable persons to suspect that
professional judgment has been improperly influenced, whether or
not it has (emphasis added)’’ [91, p137]. Thus, we need to develop
mechanisms and policies that enhance public trust in the
biomedical field (e.g., by creating ‘firewalls’ between industry
and academic researchers).
Moreover, there are many posited mechanisms for the link
between conclusions and industry ties—mechanisms that can be
subtle and unintentional. Our current regulatory system does not
incentivize industry to develop maximally informative study
designs [92], which may in turn reinforce implicit bias. For
example, industry affiliated researchers are incentivized to design
pre-clinical studies that use only those dosages that have been
associated with antiproliferative effects. Our findings suggest that
there is a need to either incentivize industry to use non-linear dose
response models or change carcinogenicity guidelines (outlined
below).
Given the lack of epidemiological data on low-dose SSRI use,
the issue of informed consent becomes a complex and critical one.
It is likely that women, especially women being prescribed
adjunctive AD therapy for depression secondary to a breast or
ovarian cancer diagnosis or as adjunctive therapy for pain and hot
flashes, would want to know about the positive cancer findings of
animal and human studies, the genotoxic properties of some ADs,
as well as the potential neoplastic/antiproliferative findings
reported in some studies. Additionally, our findings have
implications in light of the latest U.S. Preventive Services Task
Force (USPSTF) guidelines recommending that women between
the ages of 40–49 do not need routine screening for breast cancer
[93]. Non-high risk women between the ages of 40 and 49 who
have taken ADs, especially low dose SSRIs, may want to continue
to get yearly mammograms. Also, although some regulatory
agencies suggest that researchers consider using middle and low
doses for rodent carcinogenicity studies (e.g., the FDA), we
recommend that agencies require researchers to use non-linear
dose response models when assessing the carcinogenicity of drugs.
Our study has several limitations. First, some of the articles
retrieved were published prior to the development of COI policies
and standard disclosure practices. It is likely that our screening
techniques missed some industry ties and disclosure depends upon
honest reporting of those ties. Thus, our findings should be
considered de-minimis figures. Second, although we searched
multiple databases, we did not search EMBASE. However, in
light of the documented retrieval congruence between MEDLINE
and EMBASE [94] and the fact that we hand-reviewed the
reference sections of most of the articles that met study criteria, it is
unlikely that we would have missed a significant number of articles
that would have changed our study results. However, future
researchers should include EMBASE to ensure as complete a
search as possible. Third, although a random-effects meta-analysis
was conducted, results should be interpreted with caution given
that the studies included were very heterogeneous in terms of –
amongst others – design, patient population, outcomes measured,
and follow-up times. Moreover, too few studies were available to
conduct meaningful subgroup analyses accounting for some of
these characteristics. Future research should include a systematic
review of all epidemiological data on cancer risk and AD use.
Progress in the field of pharmacogenomics has led to increasing
concerns about the complex relationships among serotonin,
SSRIs, certain TCAs, prolactin, and tamoxifen, and how these
inter-relationships affect pharmacodynamics and cancer risk [95].
It is recommended that future research examine this body of
literature and investigate the association between industry funding
and qualitative conclusions regarding cancer risk.
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